Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Gain Big Money In $DAL

Delta Air Lines Inc. (DAL) rises 7.85% at 12:32 PM EST today as Amex Airline Index adds 2.36% to 34.45 point. According to Reuters, Delta expects 2012 should be “a year of earnings growth.” For the fourth quarter 2011, it expects an operating margin of 6 to 8 percent, compared with a previous forecast of 5 to 7 percent.

Ken-Heebner

Among 34 hedge funds that took positions in Delta, we list top 10 hedge funds which may reveal huge gains due to DAL’s price rise.

1. Capital Growth Management – Ken Heebner: gains $11.53 million

2. Blue Ridge Capital – John Griffin: gains $7.94 million

3. Alyeska Investment Group – Anand Parekh: gains $5.75 million

4. GMT Capital – Thomas E. Claugus: gains $3.32 million

5. Highbridge Capital Management – Glenn Russell Dubin: gains $2.80 million

6. Appaloosa Management – David Tepper: gains $1.83 million

7. Vinik Asset Management – Jeffrey Vinik: gains $1.78 million

8. Citadel Investment Group – Ken Griffin: gains $1.50 million

9. Contrarian Capital – Jon Bauer: gains $1.01 million

10. Buckingham Capital Management – David Keidan: gains $983 thousand

DISCLAIMER: These calculations assume that these hedge funds did not increase or reduce their stock positions in DAL since the end of September. We did not take into account their option positions.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!